2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Friday, March 20, 2026

5:00PM-6:00PM: Abstract Number: 105

Rheumatological Biomarkers and Symptom Progression in Pediatric Systemic Lupus Erythematosus (SLE)

Posters: Clinical and Therapeutic Aspects II

5:00PM-6:00PM: Abstract Number: 113

Risk Assessment for Pediatric Rheumatic Diseases in Children with a History of Kawasaki Disease: A Long-Term Retrospective Comparative Big Data Cohort Study

Posters: Clinical and Therapeutic Aspects II

5:00PM-6:00PM: Abstract Number: 129

Selection of Core Measures in Development of a Childhood Arthritis and Rheumatology Research Alliance based Pediatric Pain Registry for Management of Amplified Musculoskeletal Pain Syndrome

Posters: Quality, Health Services, and Education Research II

5:00PM-6:00PM: Abstract Number: 127

Setting the Stage for an Effective, Accessible, and Patient-Centered Nature-Based Intervention for Adolescents with Juvenile Idiopathic Arthritis (JIA)

Posters: Quality, Health Services, and Education Research II

5:00PM-6:00PM: Abstract Number: 107

Targeting Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Real-World Emapalumab Experience Spanning 3 Years

Posters: Clinical and Therapeutic Aspects II

5:00PM-6:00PM: Abstract Number: 109

Tarsitis in Juvenile Idiopathic Arthritis: Clinical characteristics, imaging features, and treatment Response – A multicenter retrospective study

Posters: Clinical and Therapeutic Aspects II

5:00PM-6:00PM: Abstract Number: 123

The Details Matter: A Patient Centered Approach to Overcoming Barriers in a Pediatric to Adult Rheumatology Transition Clinic

Posters: Quality, Health Services, and Education Research II

5:00PM-6:00PM: Abstract Number: 081

Therapeutic Drug Monitoring in Pediatric Rheumatology: A Survey of Providers in North America

Posters: Clinical and Therapeutic Aspects II

5:00PM-6:00PM: Abstract Number: 092

Treatment-Refractory Juvenile Idiopathic Arthritis: Clinical Features and Biologic/Targeted Synthetic DMARD Utilization Patterns in a Single-Center Cohort

Posters: Clinical and Therapeutic Aspects II

5:00PM-6:00PM: Abstract Number: 128

Trends in Medicaid Enrollment Churn Among Children with Rheumatic Disease Diagnoses, 2018-2023

Posters: Quality, Health Services, and Education Research II

6:00PM-7:00PM: Abstract Number: 138

Demographic, Clinical and Major Histocompatibility Complex (MHC) variation associated with uveitis development in children with juvenile idiopathic arthritis

Posters: Genetics and Pathogenesis II

6:00PM-7:00PM: Abstract Number: 134

More Than Meets the Eye: Broadening the Clinical Spectrum of RelA Haploinsufficiency

Posters: Genetics and Pathogenesis II

6:00PM-7:00PM: Abstract Number: 137

Preliminary Findings: Single Nuclei RNAseq of Juvenile Dermatomyositis Muscle Biopsies Suggests Unique Myositis Specific Autoantibody Cell Population

Posters: Genetics and Pathogenesis II

6:00PM-7:00PM: Abstract Number: 135

The Blood-CSF-Barrier in SLE: Volume and Blood Flow of the Choroid Plexus and Periventricular Tissue Abnormality Gradients

Posters: Genetics and Pathogenesis II

6:00PM-7:00PM: Abstract Number: 136

Transcriptomic Analysis of Ultrasound-Guided Synovial Biopsies from Patients with Juvenile Idiopathic Arthritis

Posters: Genetics and Pathogenesis II

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].